REFERENCES
1. Davies MJ, D’Alessio DA, Fradkin J,
Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in
Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes
Association (ADA) and the European Association for the Study of Diabetes
(EASD). Diabetes Care. 2018;41(12):2669-701.
2. Zheng Y, Ley SH, Hu FB. Global
aetiology and epidemiology of type 2 diabetes mellitus and its
complications. Nature Reviews Endocrinology. 2018;14(2):88-98.
3. Brown JB, Nichols GA, Perry A. The
burden of treatment failure in type 2 diabetes. Diabetes Care.
2004;27(7):1535-40.
4. Qaseem A, Barry MJ, Humphrey LL,
Forciea MA, Clinical Guidelines Committee of the American College of P.
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical
Practice Guideline Update From the American College of Physicians. Ann
Intern Med. 2017;166(4):279-90.
5. Thornberry NA, Gallwitz B.
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Best Practice & Research Clinical Endocrinology & Metabolism.
2009;23(4):479-86.
6. Nauck MA, Meier JJ. Incretin
hormones: Their role in health and disease. Diabetes, Obesity and
Metabolism. 2018;20(S1):5-21.
7. McCormack PL. Evogliptin: First
Global Approval. Drugs. 2015;75(17):2045-9.
8. Gu N, Park MK, Kim T-E, Bahng MY,
Lim KS, Cho S-H, et al. Multiple-dose pharmacokinetics and
pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase
IV inhibitor, in healthy volunteers. Drug design, development and
therapy. 2014;8:1709.
9. Jeong HU, Kim JH, Lee DY, Shim HJ,
Lee HS. In Vitro Metabolic Pathways of the New Anti-Diabetic Drug
Evogliptin in Human Liver Preparations. Molecules. 2015;20(12):21802-15.
10. Oh ES, Choi C, Kim CO, Kim KH,
Kim YN, Kim SJ, et al. Effects of clarithromycin on the pharmacokinetics
of evogliptin in healthy volunteers. J Clin Pharm Ther.
2017;42(6):689-94.
11. MFDS approval of a new,
domestically-developed, oral antihyperglycaemic agent [media
release]: Ministry of Food and Drug Safety; 2015 [Available from:https://www.mfds.go.kr/brd/m_99/view.do?seq=28999.
12. Hanefeld M. Pharmacokinetics and
clinical efficacy of pioglitazone. Int J Clin Pract Suppl.
2001(121):19-25.
13. America TP. ACTOS package insert.
2011.
14. Kajosaari LI, Jaakkola T,
Neuvonen PJ, Backman JT. Pioglitazone, an in vitro inhibitor of CYP2C8
and CYP3A4, does not increase the plasma concentrations of the CYP2C8
and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol.
2006;62(3):217-23.
15. Mikhail N. Combination therapy
with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical
consideration and therapeutic potential. Vascular health and risk
management. 2008;4(6):1221-7.
16. Sripalakit P, Maphanta S, Neamhom
P, Saraphanchotiwitthaya A, Polnok S, Yokubol D. Comparative study on
the bioequivalence of two formulations of pioglitazone tablet in healthy
Thai male volunteers. Drug development and industrial pharmacy.
2007;33(12):1362-8.
17. Food U, Administration D.
Clinical drug interaction studies—study design, data analysis, and
clinical implications guidance for industry. FDA<https://www fda
gov/downloads/drugs/guidances/ucm292362 pdf. 2017.
18. Kim HJ, Kwak WY, Min JP, Lee JY,
Yoon TH, Kim HD, et al. Discovery of DA-1229: a potent, long acting
dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Bioorganic & medicinal chemistry letters. 2011;21(12):3809-12.
19. Rosenstock J, Inzucchi SE,
Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial combination therapy
with alogliptin and pioglitazone in drug-naive patients with type 2
diabetes. Diabetes Care. 2010;33(11):2406-8.
20. Rosenstock J, Kim SW, Baron MA,
Camisasca RP, Cressier F, Couturier A, et al. Efficacy and tolerability
of initial combination therapy with vildagliptin and pioglitazone
compared with component monotherapy in patients with type 2 diabetes.
Diabetes, obesity & metabolism. 2007;9(2):175-85.
21. Bajaj M, Gilman R, Patel S,
Kempthorne-Rawson J, Lewis-D’Agostino D, Woerle HJ. Linagliptin improved
glycaemic control without weight gain or hypoglycaemia in patients with
type 2 diabetes inadequately controlled by a combination of metformin
and pioglitazone: a 24-week randomized, double-blind study. Diabet Med.
2014;31(12):1505-14.
22. Herman GA ZP, Dietrich B, et al.
The DP-IV inhibitor MK-043 enhances active GLP-1 and reduces glucose
following an OGTT in type 2 diabetics. Diabetes. 2004;52(A82).
23. Herman GA, Stevens C, Van Dyck K,
Bergman A, Yi B, De Smet M, et al. Pharmacokinetics and pharmacodynamics
of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy
subjects: results from two randomized, double‐blind, placebo‐controlled
studies with single oral doses. Clinical Pharmacology & Therapeutics.
2005;78(6):675-88.
FIGURE LEGENDS
Figure 1. Study design. Abbreviation: PK, pharmacokinetics; OGTT, oral
glucose tolerance test; EVO, evogliptin 5 mg once daily; PIO,
pioglitazone 30 mg once daily; EVO+PIO: evogliptin 5 mg + pioglitazone
30 mg once daily.
Figure 2. Mean plasma evogliptin
and pioglitazone concentration-time profiles at steady-state after EVO,
PIO, and EVO+PIO. Error bars represent standard deviations. (a)
evogliptin, linear scale, (b) evogliptin, semi-log scale, (c)
pioglitazone, linear scale, (d) pioglitazone, semi-log scale.
Figure 3. Mean (a) Δ serum glucose
and (b) Δ plasma insulin level-time profiles at steady-state after EVO,
PIO, and EVO+PIO. Error bars represent standard deviations.
Supplementary figure 1.
Mean plasma (a) evogliptin M7, (b) M8
and pioglitazone (c) M3, (d) M4 concentration-time profiles at
steady-state after EVO, PIO or EVO+PIO. Error bars represent standard
deviations.